Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical firm Icon Bioscience has completed patient enrollment in its pivotal phase III trial of its lead pipeline product IBI-10090, about four months ahead of projected timelines.
Subscribe to our email newsletter
The company is focused on using its Verisome drug-delivery platform in the development of new unique intraocular eye-care therapeutics.
IBI-10090, which employs the Verisome technology, has been designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery.
Icon VP of Clinical Development Wendy Yee Murahashi said enrollment in the randomized, double blind, and placebo-controlled Phase III trial of IBI-10090 began in December 2013 with a goal of enrolling 390 patients.
"The study achieved that enrollment goal well ahead of time due to the dedication and hard work of everyone at Icon as well as an outstanding team of investigators and study coordinators," Murahashi said.
Icon president and CEO David Tierney said IBI-10090 has, in a previous phase II study, showed a highly favorable efficacy and safety profile.
"Now, with the phase 3 study gaining substantial forward momentum, we are greatly encouraged about the nearer term prospects of transforming this promising pipeline product into a viable and valuable new ophthalmic drug," Tierney said.
"I join Wendy in applauding all the remarkably talented people engaged in the phase 3 study of IBI-10090."